ERBB2 and breast carcinoma: Adjuvant paclitaxel and trastuzumab (TH) is cost-effective for women with early-stage node-negative, HER2-positive breast cancer aged between 40 and 79 years old in the base case scenario as long as the time horizon is longer than the 12 years.